Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy within three days prior to registration for protocol therapyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFor women of childbearing potential only: a negative urine or serum pregnancy test done =< 7 days prior to pre-registration is requiredXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is requiredXx_NEWLINE_xXNot pregnant and not nursing; therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to re-registration is requiredXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is requiredXx_NEWLINE_xXNot pregnant and not nursing; women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is requiredXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXPregnancy test done within 14 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXPost-menarchal females may not participate unless a pregnancy test with a negative result has been obtainedXx_NEWLINE_xXPatients who are pregnant; pregnancy test is required for female patients of childbearing potentialXx_NEWLINE_xXPatients who are pregnant; (a negative pregnancy test is required for female patients of childbearing potential)Xx_NEWLINE_xXNegative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXNegative serum pregnancy test within 30 days prior to registration for females of childbearing potential.Xx_NEWLINE_xXNegative serum pregnancy test within 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test within 2 weeks prior to registration for women of childbearing potentialXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =< 8 days prior to registration is requiredXx_NEWLINE_xXNot pregnant and not nursing; therefore, for women of childbearing potential only, a negative (if your test schedule specifically indicates a urine or serum pregnancy test, add that information at this point) pregnancy test done =< 28 days prior to registration is requiredXx_NEWLINE_xXIf the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days prior to step 2 registration, must be negative, and, if randomized to receive radiation therapy, the woman must agree to use contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 21 days prior to study entryXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is requiredXx_NEWLINE_xXSerum or urine pregnancy test must be negative in premenopausal women within 14 days of randomization, or in women with amenorrhea of less than 12 months at time of randomization.Xx_NEWLINE_xXPregnant women, or women of childbearing potential without a negative pregnancy test within 14 days prior to randomization.Xx_NEWLINE_xXNegative pregnancy test of females with childbearing potential.Xx_NEWLINE_xXNegative serum pregnancy test if women of childbearing potential (WOCBP) (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized)Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have pregnancy excluded by appropriate testing before study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 96 hours prior to start of study drug.Xx_NEWLINE_xXNegative serum pregnancy test for women of childbearing potentialXx_NEWLINE_xXPregnant or lactating women; a negative pregnancy test in women of childbearing potential must be documented within 7 days before the first dose of study medicationXx_NEWLINE_xXNegative pregnancy test for women of childbearing potential (< 51 years of age) as per institutional policyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test performed =< 7 days prior to registration (women of childbearing potential only)Xx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potential (WOCBP)Xx_NEWLINE_xXFor all females of childbearing potential, a negative serum pregnancy test must be obtained within 3 days prior to starting study treatmentXx_NEWLINE_xXNegative pregnancy test within 2 weeks prior to treatment for women of childbearing potentialXx_NEWLINE_xXNegative pregnancy test at the Screening visit for women of childbearing potential and willingness to use adequate birth controlXx_NEWLINE_xXPregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within 14 days prior to study entry according to institutional standards for women of childbearing potential.)Xx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXFOCBP must have a negative pregnancy test =< 7 days prior to registration on studyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to study registration; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigatorXx_NEWLINE_xXA negative pregnancy test =< 7 days prior to treatment for premenopausal women and for women < 1 year after the onset of menopauseXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than (<) 12 months after menopauseXx_NEWLINE_xXWomen of childbearing potential (defined as women under the age of 55 with intact ovaries and uterus) must agree to use adequate contraception prior to study entry and for the duration of study participation; they must also have a negative urine pregnancy test within 7 days of starting treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the study entry and be practicing an effective form of contraceptionXx_NEWLINE_xXFor women of childbearing potential (defined as women with menses within the past 2 years), a negative serum pregnancy test must be documented prior to registration; NOTE: in addition to screening, serum pregnancy test must be performed on females of childbearing potential within 72 hours before the start of investigational product; when possible, these tests can be one-in-the-same (if screening pregnancy test was performed within 72 hours of first ponatinib dose, no need to repeat)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to use effective contraceptionXx_NEWLINE_xXWomen of childbearing potential must have negative pregnancy test within 24 hours of enrollmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test less than or equal to 7 days prior to registration.Xx_NEWLINE_xXNegative serum pregnancy test for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potentialXx_NEWLINE_xXFOCBP must have a negative pregnancy test within 7 days prior to registration on studyXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception up until three months after of receiving the last drug treatmentXx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the time they are receiving the study drug and for 3 months thereafter; abstinence is an acceptable method of birth control; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study; women of childbearing potential will be given a pregnancy test within 7 days prior to administration of RAD001 and must have a negative urine or serum pregnancy test; pregnancy tests should be repeated every course +/- 4 daysXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollmentXx_NEWLINE_xXIf female of childbearing potential, must have a negative pregnancy test within 7 days of initiating treatment. Childbearing potential is defined by: those who have not been surgically sterilized and/or have had a menstrual period in the past year.Xx_NEWLINE_xXA negative pregnancy test (for females of childbearing potential)Xx_NEWLINE_xXPatient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug, and agrees to abstain from activities that could result in pregnancy from Screening through 180 days after the last dose of study drug, or is of nonchildbearing potential.Xx_NEWLINE_xXPregnancy or lactation at the time of randomization or intention to become pregnant during the study. (Note: Negative serum pregnancy test must be obtained within 14 days prior to randomization).Xx_NEWLINE_xXFemales of childbearing potential who:Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)Xx_NEWLINE_xXFOCBP must have a negative pregnancy test within 7 days prior to registration on study; NOTE: a negative pregnancy test is also required within 3 days prior to first dose of pembrolizumab and therefore may need to be repeated if screening test is more than 3 days prior to first doseXx_NEWLINE_xXIf the participant is of childbearing potential, she must have a documented negative urine pregnancy test at the time of screening and randomization and no plans to become pregnant for the duration of study participation.Xx_NEWLINE_xXNegative serum/urine pregnancy test (for women of childbearing potential)Xx_NEWLINE_xXPositive pregnancy test; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued; negative serum pregnancy test will be required for women of childbearing potentialXx_NEWLINE_xXHave a negative pregnancy test result at Screening for females of childbearing potentialXx_NEWLINE_xXWomen must not be pregnant or breastfeeding; all females of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a blood or urine test to rule out pregnancy within 2 weeks prior to registrationXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test for females of childbearing potentialXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test at screeningXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entryXx_NEWLINE_xXNegative pregnancy test by urine or serum or waiver of pregnancy testing per local institutional policy within 30 days prior to randomization according to local standards for women of childbearing potentialXx_NEWLINE_xXPregnant or breast-feeding women may not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; negative serum or urine pregnancy test within 3 days prior to enrollmentXx_NEWLINE_xXFemale patients must have a negative serum pregnancy test or be of non-childbearing potential.Xx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients who have menstruated and are of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to registrationXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative serum pregnancy test done =< 7 days prior to registration is requiredXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to registrationXx_NEWLINE_xXBe of non-childbearing potential:Xx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test at screening and must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after the last dose of IMGN853 and gemcitabineXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to the administration of the study drugs for female patients of childbearing potential.Xx_NEWLINE_xXWomen of childbearing potential must have a negative urine pregnancy test at the screening visitXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXSerum or urine pregnancy test (for females of childbearing potential) negative ?7 days of starting treatmentXx_NEWLINE_xXFemale subjects of childbearing potential have a negative pregnancy test at screening. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti estrogens, or ovarian suppression.Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnancy (negative serum pregnancy test to be obtained within 6 days prior to enrollment for subjects of childbearing potential)Xx_NEWLINE_xXFemale participants of childbearing potential are to have a negative serum pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative qualitative serum pregnancy test =< 14 days prior to Step 1 registrationXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 14 days of registrationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigatorXx_NEWLINE_xXWomen of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative serum pregnancy test prior to the initiation of radiation therapyXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women <= 2 years after menopauseXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test at the time of enrollmentXx_NEWLINE_xXHave a negative pregnancy test result at Screening for females of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the start of the studyXx_NEWLINE_xXFemales of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting therapy and prior to beginning another cycle (if applicable)Xx_NEWLINE_xXWomen of childbearing potential must:\r\n* Have a negative serum or urine pregnancy test within 72 hours prior to the start of study therapy\r\n* Agree to utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study therapy is completed\r\n* Be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have negative urine pregnancy test within 7 days of day 1 (D1) of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test.Xx_NEWLINE_xXNegative serum pregnancy test at the time of enrollment for females of childbearing potentialXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have:\r\n* A negative serum or urine pregnancy test (sensitivity =< 25 IU human chorionic gonadotropin [HCG]/L) within 72 hours prior to the start of study drug administration\r\n* Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancyXx_NEWLINE_xXSerum/urine pregnancy test (for females of childbearing potential) that is negative within 72 hours prior to initiation of first dose of treatment (a patient is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active)Xx_NEWLINE_xXHas a negative serum pregnancy test within 7 days of first dose of study treatment (female patients of childbearing potential)Xx_NEWLINE_xXWomen must not be pregnant or breastfeeding; females of childbearing potential should have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL); the first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing lenalidomideXx_NEWLINE_xXPregnancy or lactation at the time of proposed study entry. Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy such as an intrauterine device or condom with spermicide. (Note: Women of childbearing potential must have a negative serum pregnancy test within 3 weeks of study registration).Xx_NEWLINE_xXWomen should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the studyXx_NEWLINE_xXNegative pregnancy test (within 7 days of enrollment) in women of childbearing potentialXx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 14 days of registration.Xx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 yearXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subjects of childbearing potential must be nonpregnant, nonlactating, and have a negative pregnancy test result at Screening and Day 1 of Cycles 1-6.Xx_NEWLINE_xXNegative pregnancy test done ? 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or nursing women. \r\n* NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test (urine or serum) within 21 days prior to the start of the study drug treatment and must agree to use adequate birth control if conception is possible during the study and up to 30 days after the completion of adjuvant therapyXx_NEWLINE_xXWomen of childbearing potential who are not using an effective method of contraception are excluded. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRSXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 7 days of the start of treatmentXx_NEWLINE_xXNegative urine or serum pregnancy test for women of childbearing potential\r\n* NOTE: females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXPregnant or lactating, or intending to become pregnant during the study\r\n* Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drugXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWithin 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Negative serum pregnancy test (female subjects of childbearing potential).Xx_NEWLINE_xXFor female subjects of childbearing potential, a negative serum pregnancy test.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test at screening and =< 72 hours prior to day 1 of study treatmentXx_NEWLINE_xXNegative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test at the time of enrollment for females of childbearing potentialXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 21 days prior to Study Day 0.Xx_NEWLINE_xXPatients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screeningXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 10-14 days prior to enrollmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the start of nivolumab.Xx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within 28 days of study entry; female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative pregnancy test (women of childbearing potential)Xx_NEWLINE_xXFemale participants of childbearing potential must have negative results for pregnancy test performed:Xx_NEWLINE_xXWomen of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment; women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)Xx_NEWLINE_xXFemale participants who are pregnant or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to randomization; all women of childbearing potential must be willing to comply with an acceptable birth control regimen to prevent pregnancy while receiving treatment and for 3 months after treatment is discontinued as determined by the Investigator; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; (note: a woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives)Xx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative pregnancy test within 14 days prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subjects of childbearing age must have a negative serum pregnancy test at study entryXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollmentXx_NEWLINE_xXPregnant females are excluded; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of radiation therapyXx_NEWLINE_xXPregnant or nursing women; NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXAny woman of childbearing potential, unless she: Agrees to take appropriate precautions to avoid becoming pregnant (with at least 99% certainty) during the study and has a negative serum pregnancy test within 7 days prior to starting treatment.Xx_NEWLINE_xXNegative serum pregnancy test for persons of childbearing potential =< 7 days prior to registrationXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative pregnancy test at screening; childbearing potential is defined as: participants who have not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test.Xx_NEWLINE_xXNon pregnant and non-nursing women; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXPregnancy and contraception:\r\n* Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential\r\n* Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last avelumab treatment administration if the risk of conception existsXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrolmentXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only; Note: patients must agree to adequate birth control during the study and for up to 6 months after discontinuation of study medicationXx_NEWLINE_xXPregnancy, lactation, or breast-feeding; women of childbearing potential must have a negative urine pregnancy test at screeningXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXSerum or urine pregnancy test (for females of childbearing potential) negative at screening and at the baseline visit (before the patient may receive the investigational product)Xx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraceptionXx_NEWLINE_xXPatients of childbearing potential must have a negative pregnancy test within 7 days prior to treatment start to be eligibleXx_NEWLINE_xXPregnant females are excluded; females of childbearing age/menstruating must confirm that either they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapyXx_NEWLINE_xXNegative urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential onlyXx_NEWLINE_xXNegative serum pregnancy test within 2 weeks of enrollment for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 yearXx_NEWLINE_xXNegative serum pregnancy test within 2 weeks of lymphodepletion chemotherapy for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 yearXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test at screening within 14 days prior to randomizationXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXFor females of childbearing potential, a negative urine pregnancy test must be documented prior to randomization.Xx_NEWLINE_xXPregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancyXx_NEWLINE_xXFemales of childbearing potential must have a negative urine or serum pregnancy test within 1 week prior to the start of treatmentXx_NEWLINE_xXWomen of childbearing potential must have negative pregnancy test prior to initiating study treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 1 day prior to administration of the first dose of chemotherapyXx_NEWLINE_xXFemales of childbearing potential who:Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)Xx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 30 days prior to randomization. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.Xx_NEWLINE_xXA woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 14 days prior to initiating study treatmentXx_NEWLINE_xXNegative serum pregnancy test within 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXIf a female of childbearing potential, has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug; if the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required; Note: Women of childbearing potential (WoCP) are any women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation; permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion; WoCP include non-women who have experienced menopause onset < 12 months prior to enrollmentXx_NEWLINE_xXDONOR: A serum or urine pregnancy test for females of reproductive potential must be conducted within 7 days prior to initiation of apheresisXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration; women of non-childbearing potential are defined as those who have no uterus, ligation of the fallopian tubes, are naturally postmenopausal for at least 12 consecutive months or have undergone surgical removal of the ovariesXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to enrollment. Within the frame of this study, female patients of childbearing potential and male patients with partners of childbearing potential must use an effective method of birth control, as described below, as well as their partners. Patients enrolled in the Dose Finding Portion of the Study:Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential onlyXx_NEWLINE_xXNegative serum or urine pregnancy test at screening for women of childbearing potentialXx_NEWLINE_xXPregnant or breastfeeding; a negative serum pregnancy test is required no more than 14 days before study entryXx_NEWLINE_xXPatients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected timeframe of the study, starting from the time of the Screening Visit through 3 months (90 days) after the last OBP-301 administration. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at each visit before administration of OPB-301. A female not of childbearing potential is one who has undergone bilateral oophorectomy or who has had no menses for 12 consecutive months.Xx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to cycle 1/day 1 for women of childbearing potentialXx_NEWLINE_xXUrine pregnancy test is negative for women of childbearing potential, within 14 days before study treatmentXx_NEWLINE_xXPregnancy or lactating females; women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to Step 2 registrationXx_NEWLINE_xXWomen of child bearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days prior to investigational product administration and a negative urine pregnancy test within the 3 days prior to the first investigational product administration, or a negative serum pregnancy test within the 3 days prior to the first investigational product administrationXx_NEWLINE_xXNegative pregnancy test and willingness to utilize contraception among women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test at screening for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test (sensitivity =< 25IU HCG/L) within 4 weeks prior to registration and will be repeated within 72 hours prior to the start of study drug administrationXx_NEWLINE_xXPregnancy or breastfeeding; women (patients or partners of male patients) of childbearing potential (WOCBP) must practice acceptable methods of birth control to prevent pregnancy; all WOCBP MUST have a negative pregnancy test within 4 weeks prior to registration, and this must be repeated within 72 hours prior to first receiving ruxolitinib; if the pregnancy test is positive, the patient must not receive ruxolitinib and must not be enrolled in the studyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trialXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test at screening; women of childbearing potential are defined as those who have not been surgically sterilized and have had a menstrual period in the past yearXx_NEWLINE_xXPregnant or breastfeeding - females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancyXx_NEWLINE_xXDONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within 7 days prior to stem cell mobilizationXx_NEWLINE_xXNegative pregnancy test within 14 days of day 1 cycle 1 for female patients of childbearing potential.Xx_NEWLINE_xXSex and reproductive status; a) women of childbearing potential (WOCBP) who are pregnant or breastfeeding; b) women with a positive pregnancy test at enrollment or prior to administration of study medicationXx_NEWLINE_xXWomen of childbearing potential must not be pregnant with a negative urine pregnancy test within 72 hours prior to registration and non-lactating; postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential; woman status post oophorectomy or hysterectomy are considered non-childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to cycle 1 day 1 and agree to use effective contraception, throughout the treatment period, and for 4 months after the last dose of study treatmentXx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within 14 days of registrationXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 30 days prior to enrollment. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.Xx_NEWLINE_xXWomen of childbearing potential must have a negative urine or blood pregnancy test within 14 days of study enrollmentXx_NEWLINE_xXNegative serum pregnancy test at screening for women of childbearing potentialXx_NEWLINE_xXFOCBP must have a negative pregnancy test within 7-10 days prior to receiving study drugXx_NEWLINE_xXFemales of childbearing potential must have negative results for pregnancy test performed:Xx_NEWLINE_xXNegative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potentialXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative urine pregnancy test within 7 days of study entryXx_NEWLINE_xXNegative serum pregnancy test at screening for women of childbearing potentialXx_NEWLINE_xXNot pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of apheresisXx_NEWLINE_xXFOCBP must have a negative pregnancy test =< 7 days prior to registration on studyXx_NEWLINE_xXNegative serum pregnancy test within =< 7 days prior to the first dose of study drug, for women of childbearing potential onlyXx_NEWLINE_xXWomen who are pregnant or breast-feeding, or intend to become pregnant during the study; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the investigational productXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have two negative pregnancy tests; the first test should be performed within 10-14 days of study entry, and the second test within 24 hours prior to prescribing pomalidomideXx_NEWLINE_xXPregnant or breast-feeding patients; women of childbearing potential (WOCBP) must have a serum pregnancy test performed a maximum of 7 days before the start of study treatment, and a negative result must be documented before the start of study treatmentXx_NEWLINE_xXFemale patients of childbearing potential, negative urine pregnancy test done =< 7 days prior to study registrationXx_NEWLINE_xXDONOR: Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of apheresisXx_NEWLINE_xXPregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women; breastfeeding must be discontinued because of unknown but potential risks in the nursing infantXx_NEWLINE_xXSerum/urine pregnancy test (for females of childbearing potential) that is negative at screening and immediately prior to initiation of treatment (first dose).Xx_NEWLINE_xXPregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to randomization, irrespective of the method of contraception used, are excluded from this study; breastfeeding must be discontinued prior to study entryXx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period they are receiving the study drug and for 3 months thereafter; abstinence is an acceptable method of birth control; women of childbearing potential will be given a pregnancy test within 7 days prior to administration of cabozantinib and must have a negative urine or serum pregnancy testXx_NEWLINE_xXBe of non-childbearing potential:Xx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to study entry; pregnancy test must be repeated if performed > 14 days before administration of MGCD516)Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative serum pregnancy =< 7 days prior to registrationXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXAll women of childbearing potential must have a negative urine or serum pregnancy test at screening.Xx_NEWLINE_xXSerum pregnancy test (for females of childbearing potential) negative at screeningXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to registration; women of non-childbearing potential are defined as those who have no uterus, ligation of the fallopian tubes, or permanent cessation of ovarian function due to ovarian failure or surgical removal of the ovaries; all others are considered women of child bearing potentialXx_NEWLINE_xXPregnant or breast feeding; the agents used in this study include pregnancy category D: known to cause harm to a fetus; females of childbearing potential must have a negative pregnancy test prior to starting therapyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrollmentXx_NEWLINE_xXNegative urine or serum pregnancy test for women of childbearing potentialXx_NEWLINE_xXFor women of childbearing age, negative pregnancy test within 14 days prior to registrationXx_NEWLINE_xXPregnant or breast feeding women are excluded from participating in this study; WOCBP must have a negative serum pregnancy test within 7 days of the first administration of decitabineXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 7 days of starting treatmentXx_NEWLINE_xXFemales with childbearing potential must have had a negative urine or serum pregnancy test =< 7 days before the first dose of deferasirox and must also not be breastfeedingXx_NEWLINE_xXA negative pregnancy test (only for women of childbearing potential [WOCBP])Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 7 days following the last dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only \r\n* NOTE: Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test (or serum) within 14 days prior to registration; (Note: contraception in patients with reproductive capacity will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years)Xx_NEWLINE_xXWomen of childbearing age must have a negative serum pregnancy test to meet eligibility per Duke policyXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test; women of childbearing potential are defined as all women except women who are postmenopausal or who have had a hysterectomy; postmenopausal will be defined as women over the age of 55 who have not had a menstrual period in at least one year; breastfeeding should be discontinued if the mother is treated with E7 TCR transduced peripheral blood lymphocyte (PBL); these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXNot pregnant or breastfeeding; a negative pregnancy test is required within 14 days of registration for pre- or perimenopausal (i.e., last menstrual period within one year of registration) womenXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test < 1 week prior to enrollment.Xx_NEWLINE_xXA woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 14 days prior to study registration; Note: If study treatment is not initiated within 7 days after the pregnancy test, the pregnancy test must be repeatedXx_NEWLINE_xXA negative serum pregnancy test at screening for women of childbearing potential (WOCBP)Xx_NEWLINE_xXNegative pregnancy test in a woman with childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilizationXx_NEWLINE_xXNegative urine pregnancy test within 1 week prior to Cycle 1 Day 1 for each woman of childbearing potentialXx_NEWLINE_xXNegative urine pregnancy test within 1 week prior to Cycle 1 Day 1 for each woman of childbearing potentialXx_NEWLINE_xXNegative pregnancy test in females of reproductive ageXx_NEWLINE_xXPersons of reproductive potential must agree to an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped\r\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 8 days prior to start of study drug administrationXx_NEWLINE_xXPHASE I: Negative urine pregnancy test =< 3 days prior to course 1 day 1 (C1D1) (women of childbearing potential only)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 3 days of signing consentXx_NEWLINE_xXWomen of childbearing potential must have a negative qualitative serum pregnancy test =< 2 weeks prior to study entryXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of study entryXx_NEWLINE_xXNegative urine or serum pregnancy test done =< 21 days prior to computed tomography (CT) simulation, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or breast feeding; females of childbearing potential must have a negative pregnancy test prior to starting therapyXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >=1 yearXx_NEWLINE_xXPregnancy restrictions - Women of childbearing potential must have a negative B-HCG documented within 7 days prior to registrationXx_NEWLINE_xXWomen who are pregnant or lactating. Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment.Xx_NEWLINE_xXPregnant and breastfeeding women will be excluded; women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatmentXx_NEWLINE_xXNegative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 yearXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 yearXx_NEWLINE_xXINCLUSION CRITERIA FOR TNBC: Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 yearXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test and agree to use contraception during on-study protocol treatment.Xx_NEWLINE_xXNegative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXIf a woman is of childbearing potential, a negative serum pregnancy test must be documentedXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of pregnancy potential must practice an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; women must continue birth control for the duration of the trial and at least 3 months after the last dose of study drug; pregnant or breast-feeding women are excluded; all WOCBP must have a negative pregnancy test prior to first receiving investigational product; if the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the studyXx_NEWLINE_xXA negative serum or urine pregnancy test must be done within 72 hours before the first dose of the study medication for women of childbearing potential as per institutional guidelines; post-menopausal women (defines as no menses for at least 1 year) and surgically sterilized women are not required to undergo pregnancy testXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of study entryXx_NEWLINE_xXIf a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the studyXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXIf a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the studyXx_NEWLINE_xXFemale patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollmentXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 14 days of treatment.Xx_NEWLINE_xXPregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancyXx_NEWLINE_xXWomen of childbearing potential mustXx_NEWLINE_xXWOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG); the first should be performed within 10 to 14 days and the second within 24 hours prior to the start of the study drug; a prescription for lenalidomide for a female of childbearing potential must not be issued by the prescriber until negative pregnancy tests have been verified by the prescriberXx_NEWLINE_xXNegative urine or blood pregnancy test for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screening and within 24 hours prior to the start of each nivolumab doseXx_NEWLINE_xXNegative pregnancy test within 7 days prior to commencement of dosing in premenopausal women, women of non childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 yearXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 72 hours of study entryXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXPregnant or breast-feeding patients; women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatmentXx_NEWLINE_xXPregnant or lactating women; female study participants of reproductive potential must have a negative serum pregnancy test at enrollmentXx_NEWLINE_xXWomen of childbearing potential must have a negative blood pregnancy test at the screening visitXx_NEWLINE_xXPregnant or nursing; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXSerum or urine pregnancy test (for females of childbearing potential) negative =< 7 days of registrationXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entryXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potentialXx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Females of childbearing potential must have a negative serum pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the studyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have negative pregnancy test within 72 hours prior to day (D)1 of treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXFemales with childbearing potential must have a negative serum pregnancy test within 14 days prior to treatment startXx_NEWLINE_xXWomen of childbearing potential must:\r\n* Have a negative serum or urine pregnancy test within 72 hours prior to the start of study therapy\r\n* Agree to utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study therapy is completed\r\n* Be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancyXx_NEWLINE_xXFor all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatmentXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 7 daysXx_NEWLINE_xXHave a negative pregnancy test if a female with childbearing potentialXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test confirmed within 7 days prior to enrollmentXx_NEWLINE_xXFor women of childbearing potential only: Negative pregnancy test =< 10-14 days prior to registration; NOTE: the patient must have an additional negative pregnancy test =< 24 hours prior to receiving the initial prescription of lenalidomide, per requirements of the REVLIMID Risk Evaluation and Mitigation Strategies (REMS) programXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.Xx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to CRS and must be practicing an effective form of contraception during the study periodXx_NEWLINE_xXDONOR: Pregnant females\r\n* NOTE: a serum or urine pregnancy test for females of reproductive potential must be conducted within 7 days prior to initiation of recipient’s conditioning regimenXx_NEWLINE_xXFemale patients who are pregnant or breast-feeding (confirmation that the patient is not pregnant must be by a negative pregnancy test result obtained during screening; pregnancy testing is required of women of childbearing potential but not required for post-menopausal or surgically, sterilized women)Xx_NEWLINE_xXA woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 7 days prior to initiating study treatmentXx_NEWLINE_xXNursing women, women of childbearing potential with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception (such as birth control pills, intrauterine device [IUD], diaphragm, abstinence, or condoms by their partner) over the entire course of the study; women of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeedingXx_NEWLINE_xXPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.Xx_NEWLINE_xXNegative pregnancy test for women of childbearing potential within 14 days prior to registrationXx_NEWLINE_xXWomen of childbearing potentialXx_NEWLINE_xXPatients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; if applicable, patients must discontinue breastfeeding prior to the first date of treatment on this studyXx_NEWLINE_xXFemales of childbearing potential must have a negative urine pregnancy test at screening and be willing to have additional urine pregnancy tests during the study; females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomyXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 1 week prior to treatment with 131I-MIBGXx_NEWLINE_xXPregnant and/or breastfeeding; premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entryXx_NEWLINE_xXPregnant and/or breastfeeding; premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entry (Arm B)Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 7 days of start of study treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the investigational productXx_NEWLINE_xXPregnant or lactating women; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to the initiation of radiation therapyXx_NEWLINE_xXPregnant and/or breastfeeding; patients of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).Xx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 14 days of radiation startXx_NEWLINE_xXPregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within 14 days prior to study entry according to institutional standards for women of childbearing potential.)Xx_NEWLINE_xXNegative pregnancy test in female patients of childbearing potentialXx_NEWLINE_xXNegative pregnancy test in female patients of childbearing potentialXx_NEWLINE_xXSTEP 2: Negative pregnancy test in female patients of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential who have a positive result on screening urine pregnancy testXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative serum pregnancy test (women of childbearing potential only)Xx_NEWLINE_xXAgreement by females of childbearing potential and sexually active males to use an effective method of contraception while participating in this study; women of childbearing potential must have a negative pregnancy test < 2 weeks prior to registrationXx_NEWLINE_xXNegative serum pregnancy test for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test for women of childbearing potentialXx_NEWLINE_xXPregnant or lactating - women of childbearing potential should use appropriate precautions to avoid becoming pregnant; females of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study treatment startXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 7 days; women of childbearing potential and men must agree to use contraception at study entry and for the duration of active study treatmentXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to entering this studyXx_NEWLINE_xXFor females of childbearing age, they may participate it they: a. have a negative serum or urine pregnancy test within 10 to 14 days of enrolling (a second pregnancy test will be performed within 24 hours (hrs) of starting therapy and both negative pregnancy tests will be required for starting therapy); b. agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 28 days after discontinuing treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 7 days of study entry if premenopausalXx_NEWLINE_xXNegative pregnancy test at the time of SRS in any patient who could be pregnantXx_NEWLINE_xXA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trialXx_NEWLINE_xXAre pregnant or breast-feeding. In women of childbearing potential, a negative serum pregnancy test is required prior to study treatment.Xx_NEWLINE_xXPregnant females are excluded; women of childbearing age/menstruating must confirm they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapyXx_NEWLINE_xXNegative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)Xx_NEWLINE_xXFemales of childbearing potential must not be pregnant; this will be confirmed by a negative serum pregnancy test within 14 days prior to starting study treatmentXx_NEWLINE_xXNegative pregnancy test in women of childbearing ageXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment.Xx_NEWLINE_xXWomen of childbearing potential must have:\r\n* A negative serum or urine pregnancy test (sensitivity =< 25 IU human chorionic gonadotropin [HCG]/L) within 72 hours prior to the start of study drug administration\r\n* Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancyXx_NEWLINE_xXA negative pregnancy test within 7 days prior to registration for women of childbearing potential; in addition, male and female participants must commit to adequate contraception while on studyXx_NEWLINE_xXWomen of reproductive potential must have negative urine pregnancy testXx_NEWLINE_xXFemales of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to study entryXx_NEWLINE_xXWomen who are pregnant or lactating; all female patients with reproductive potential must have a negative pregnancy test prior to day 1Xx_NEWLINE_xXNegative serum pregnancy test within 72 hours prior to the first study dose in all women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXFor women of childbearing age, a negative pregnancy test performed within 14 days of surgeryXx_NEWLINE_xXNegative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non-childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)Xx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemales of childbearing potential must have a negative serum ?-Hcg pregnancy test result within 7 days of first study dose. Female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have ?- Hcg pregnancy test waived.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to FDG-PET-MRIXx_NEWLINE_xXA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to initiation of therapyXx_NEWLINE_xXA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trialXx_NEWLINE_xXWomen of childbearing potential must have a pregnancy test at screeningXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXWomen who are pre-menopausal must have a negative serum pregnancy test; subjects must agree to use appropriate contraception until 4 weeks after the completion of chemotherapyXx_NEWLINE_xXFor females of childbearing potential, a negative pregnancy test must be documented prior to randomizationXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potentialXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative pregnancy test performed =< 7 days prior to registration for women of childbearing potential onlyXx_NEWLINE_xXNegative pregnancy test (urine or serum), within 7 day prior to day 1 of FOLFIRI in women of childbearing potentialXx_NEWLINE_xXFor women of childbearing potential, negative urine or serum pregnancy test within 6 weeks prior to study entryXx_NEWLINE_xXFemales of childbearing potential must have negative serum or urine pregnancy test within 7 days prior to study entry; the effects of lapatinib on the developing human fetus are unknown; however, bevacizumab is known to be teratogenic and detrimental to fetal development and endometrial proliferation, thereby having a negative effect on fertilityXx_NEWLINE_xXWomen of child-bearing potential must have a negative serum pregnancy test at screening; in addition to having a negative pregnancy test confirmed at screening, all female participants of childbearing potential must have a negative pregnancy test confirmed within 48 hours prior to dosing with the study drugXx_NEWLINE_xXWomen of childbearing potential who are not using an effective method of contraception are excluded; women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRSXx_NEWLINE_xXA urine pregnancy test will be performed on each fertile premenopausal female prior to entry into the study; patients with childbearing potential must employ effective contraception during the radiation therapyXx_NEWLINE_xXWomen who are able to conceive and unwilling to practice and effective method of birth control; women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to treatmentXx_NEWLINE_xXPregnant women will not be eligible; women of childbearing potential must have a negative pregnancy test before starting therapyXx_NEWLINE_xXNegative pregnancy test of the blood within 7 days of starting treatment in female patient of childbearing potentialXx_NEWLINE_xXBe of non-childbearing potential:Xx_NEWLINE_xXOr, if of childbearing potential:Xx_NEWLINE_xXNegative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential onlyXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or breastfeeding; females of childbearing potential must have a negative pregnancy test prior to starting therapyXx_NEWLINE_xXFemale and male subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method; women of non-child-bearing potential may be included if they are either surgically sterile or have been post-menopausal for > 1 year\r\n* Note: Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days prior to receiving therapy; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients should be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potentialXx_NEWLINE_xXWomen of child-bearing potential must have a negative serum pregnancy test during Screening and a negative urine pregnancy test within 24 hours prior to first dose of study treatment. Non-childbearing is defined as greater than one year postmenopausal or surgically sterilized.Xx_NEWLINE_xXPregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within 14 days prior to study entry according to institutional standards for women of childbearing potential.)Xx_NEWLINE_xXBoth male and female patients and their partners of childbearing potential must agree to use appropriate birth control methods (birth control pills, barriers, or abstinence) throughout the study duration (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.Xx_NEWLINE_xXNegative serum pregnancy test result within 14 days prior to study drug among women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 3 days prior to study initiation.Xx_NEWLINE_xXNegative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 7 days of starting treatmentXx_NEWLINE_xXFor females, a negative pregnancy testXx_NEWLINE_xXA negative pregnancy test (if female of childbearing potential).Xx_NEWLINE_xXChildbearing age women with negative pregnancy testXx_NEWLINE_xXWomen of childbearing potential who have a negative pregnancy test within 7 days of the first dose of sorafenib in this long term extension program.Xx_NEWLINE_xXPregnant women or women of childbearing potential and not using methods to avoid pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential; no breast-feeding while on study.Xx_NEWLINE_xXWomen of childbearing potential who have negative pregnancy test resultsXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXPregnancy or lactation at the time of randomization or intention to become pregnant during the study; (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 72 hours prior to randomization)Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative urine and/or serum pregnancy test within 5 days prior to randomization (MLT Arm and Control Arm) ;Xx_NEWLINE_xXNegative pregnancy test in women of childbearing potentialXx_NEWLINE_xX6. Women must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration.Xx_NEWLINE_xXPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 24 hours of study entryXx_NEWLINE_xXPregnancy or breastfeeding, or intention of becoming pregnant during the study. Female subjects must either be of non-reproductive potential or have a negative serum pregnancy test result within 14 days prior to initiation of study treatmentXx_NEWLINE_xXNegative serum pregnancy test done ? 7 days prior to registration, for persons of childbearing potential onlyXx_NEWLINE_xXFemale patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline. Women of childbearing potential must have a negative serum pregnancy test as a part of eligibility, within 28 days of registration.Xx_NEWLINE_xXNegative pregnancy test done at screening and ? 3 days (72 hours) prior to registration, for women of childbearing potentialXx_NEWLINE_xXPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry and again within 24 hours prior to first treatment.Xx_NEWLINE_xXIf female: not breastfeeding; agrees to not attempt to become pregnant during the study; is surgically sterile or at least 2-years postmenopausal, or if of childbearing potential, has negative screening serum pregnancy test (if serum pregnancy test results are not available at the time of enrollment, a negative urine pregnancy test is required within 24 hours.); if of childbearing potential (including being < 2 years postmenopausal), is willing to practice sexual abstinence or use an effective dual form of contraception with her partner (eg, 2 barrier methods, barrier method plus hormonal method) during treatment and for ? 28 days after the last dose of any study therapy (IV or oral)Xx_NEWLINE_xXNegative pregnancy test performed =< 7 days prior to registration (women of childbearing potential only)Xx_NEWLINE_xXPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine.Xx_NEWLINE_xXPregnant or breastfeeding - The agents used in this study fall under Pregnancy Category D - Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days of study drug administrationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to initiation of treatment AND confirmed prior to initiation of treatment on day 1Xx_NEWLINE_xXDONORS: Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization startXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollmentXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen who are pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of nivolumab.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and must agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 30 days of registrationXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgement of the investigatorXx_NEWLINE_xXPregnant or lactating women; pregnant women are excluded from this study; women of childbearing potential must have a negative pregnancy test per standard of care prior to the surgery for tumor removal; a second pregnancy test must be performed 7 days prior to the first vaccination and must be negative; breastfeeding should be discontinued if the mother is treated on studyXx_NEWLINE_xXFemale patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinibXx_NEWLINE_xXNegative serum pregnancy test =< 7 days prior to registration for women of childbearing potential\r\n* NOTE: women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment, andXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is requiredXx_NEWLINE_xXNegative urine or serum pregnancy test for women of childbearing potential within 7 days prior to study entryXx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy test within the 7 days prior to the first study drug administration.Xx_NEWLINE_xXNegative serum pregnancy test done =< 14 days prior to randomization, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test (within 7 days prior to study registration)Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test and agree to use two forms of acceptable contraceptive measures from the time of consent through 120 days after discontinuation of study drug administration.Xx_NEWLINE_xXFOCBP must have a negative pregnancy test =< 7 days prior to registrationXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXA woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 7 days prior to initiating study treatmentXx_NEWLINE_xXFor women of childbearing potential, a negative serum pregnancy test within 14 days of registrationXx_NEWLINE_xXWomen who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 28 days prior to initiation of study drugXx_NEWLINE_xXPatients who are pregnant; a pregnancy test is required for female patients of childbearing potentialXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXARM A: Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential onlyXx_NEWLINE_xXARM B: Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or breast feeding; all females of childbearing potential must have a blood or urine pregnancy test within 2 weeks prior to enrollment to rule out pregnancyXx_NEWLINE_xXWomen of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment, women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)Xx_NEWLINE_xXNegative pregnancy test (either urine or serum) within 14 days prior to randomization for all women of childbearing potential (above)Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy test at screeningXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFor women of childbearing potential only: negative urine or serum pregnancy test done =< 7 days prior to registrationXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapyXx_NEWLINE_xXNegative serum pregnancy test within 7 days of treatment initiation with ibrutinib in women of childbearing potential (WOCBP)Xx_NEWLINE_xXNegative (serum or urine) pregnancy test done =< 7 days prior to registration, for women of childbearing potential only; NOTE: a second pregnancy test must be performed within 24 hours prior to the start of lenalidomide; the subject may not receive lenalidomide until the study doctor has verified that the results of these pregnancy tests are negativeXx_NEWLINE_xXParticipant is neither pregnant nor nursing:\r\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent of HCG) within 7 days prior to start of study medication; it is the investigators’ responsibility to repeat the pregnancy test should start of treatment be delayedXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration or randomizationXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant women are excluded from this study; women of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative pregnancy test at screening; females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy); however, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, or ovarian suppression or other reasonsXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration (for women of childbearing potential only)Xx_NEWLINE_xXPregnant or breast feeding; the agents used in this study have the potential to harm a fetus; radiation is a known teratogen; there is insufficient information regarding potential for fetal harm during immunotherapy at this time; biological females of childbearing potential must have a negative pregnancy test within 14 days of registrationXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 14 days of the administration of the first study treatment; women must not be lactatingXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXSerum pregnancy test for female patients of childbearing potential, =< 72 hours prior to study entry; women of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXNegative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drugXx_NEWLINE_xXNegative serum pregnancy test within 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXFemale patients who are pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy; WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational productXx_NEWLINE_xXFor women of childbearing potential, a serum pregnancy test within 72 hours prior to registrationXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to start of study treatmentXx_NEWLINE_xXFemale patients of childbearing potential and sexually-active male patients must agree to use an effective method of contraception while participating in this study; women of childbearing potential must have a negative pregnancy test =< 2 weeks prior to registrationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screeningXx_NEWLINE_xXWomen of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of starting the vemurafenibXx_NEWLINE_xX-Pregnant or lactating women.  Women of childbearing potential must have a negative\n             pregnancy test.  Pregnancy testing is not required for post-menopausal or surgically\n             sterilized women.Xx_NEWLINE_xXWomen of childbearing potential only: negative serum pregnancy test done =< 14 days prior to registrationXx_NEWLINE_xXNegative serum or urine pregnancy test within 3 days prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXFemale patients of childbearing potential must have negative serum pregnancy test within 14 days of starting protocol therapyXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes and continue use for 8 weeks after completing treatment; hormonal contraceptives are not acceptable as a sole method of contraceptionXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXFor women of childbearing potential, a negative serum or urine pregnancy testXx_NEWLINE_xXFor women of childbearing potential, a negative serum pregnancy test within 14 days prior to step 2 registrationXx_NEWLINE_xXIf female, patient must not be pregnant or breastfeeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancyXx_NEWLINE_xXFor women of childbearing potential, a negative serum pregnancy test within 2 weeks of registrationXx_NEWLINE_xXNegative pregnancy test for females of childbearing potentialXx_NEWLINE_xXIf of childbearing potential must have a negative pregnancy test and use an effective method to avoid pregnancy for the duration of the trial and for at least 6 months after completion of study therapyXx_NEWLINE_xXPrior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancyXx_NEWLINE_xXA negative pregnancy test in female patients of childbearing potential; women must not be breast-feedingXx_NEWLINE_xXFemales of childbearing potential must also agree to ongoing pregnancy testingXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the study entry and be practicing an effective form of contraceptionXx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXFemale subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy and on the first day of study drug administration.Xx_NEWLINE_xXWomen must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to enrollment; women of childbearing potential and men must agree to use adequate contraception prior to enrollment and for the duration of study participationXx_NEWLINE_xXFemales of childbearing potential that do not have a negative pregnancy test.Xx_NEWLINE_xXNegative Serum pregnancy test for females of childbearing potentialXx_NEWLINE_xXPatients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; pregnant women are excluded from this studyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 7 days of study entryXx_NEWLINE_xXNegative blood pregnancy test at Screening for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potential within 2 weeks of studyXx_NEWLINE_xXA negative pregnancy test (for females of childbearing potential).Xx_NEWLINE_xXPremenopausal women must have a negative serum pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopauseXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization, and must not be breastfeeding and must agree to use contraceptive for duration of study.Xx_NEWLINE_xXIf female of childbearing potential, serum pregnancy test is negativeXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to registration\r\n* Childbearing potential is defined as: participants who have not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus)Xx_NEWLINE_xXPregnancy or lactation period. Women of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment and for 90 days after discontinuation. A serum pregnancy test must be negative in premenopausal women or women with amenorrhea of less than 12 months.Xx_NEWLINE_xXFemales of childbearing potential who:Xx_NEWLINE_xXFemales with childbearing potential: Have had a negative serum pregnancy test ?7 days before the first dose of study drug and also must not be breastfeeding.Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXNegative blood pregnancy test at the screening visit for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test for women of childbearing potential within 14 days of study registrationXx_NEWLINE_xXNegative serum pregnancy test within 2 weeks prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopauseXx_NEWLINE_xXPregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to registration and must implement adequate contraceptive measures during study treatment;Xx_NEWLINE_xXNegative serum pregnancy test within three days prior to registration for women of childbearing potentialXx_NEWLINE_xXFor female patients of childbearing potential, have a negative pregnancy test documented prior to randomization.Xx_NEWLINE_xXPregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential.)Xx_NEWLINE_xXNegative serum pregnancy test if female and of childbearing potentialXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXFemales of childbearing potential have a negative serum pregnancy test (preceding 72 hours of first day of BBI608 treatment).Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) with negative serum or urine pregnancy test within 7 days of day 1 (D1) of treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomideXx_NEWLINE_xXWomen must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR they must have a negative serum pregnancy test prior to randomization.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment. Female subject considered not of childbearing potential must be documented as being surgically sterile or post-menopausal for at least 1 year. Women of childbearing potential and men must agree to use adequate contraception.Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine pregnancy test prior to patient registrationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test prior to registration.Xx_NEWLINE_xXNegative serum pregnancy test in females of childbearing potentialXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the investigational product; a positive pregnancy test will prohibit the subject from receiving the investigational productXx_NEWLINE_xXPregnant or breastfeeding, or intending to become pregnant during the study; women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatmentXx_NEWLINE_xXAny patients of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXWOCBP must have a negative serum pregnancy test within 14 days prior to the first dose of ipilimumab/nivolumabXx_NEWLINE_xXWomen of reproductive potential must have a negative serum pregnancy test obtained within 3 days before the start of anetumab ravtansineXx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose.Xx_NEWLINE_xXFemale patients of childbearing potential must have negative urine pregnancy test no more than 3 days prior to starting study treatmentXx_NEWLINE_xXPregnancy Status Female patients of childbearing potential, must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test.Xx_NEWLINE_xXNegative pregnancy test for females of childbearing potentialXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccineXx_NEWLINE_xXNegative pregnancy test and willingness to utilize contraception among women of childbearing potentialXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test. The definition of adequate contraception will be based on the judgment of the investigator.Xx_NEWLINE_xXWomen of childbearing age with a negative pregnancy test documented prior to enrollmentXx_NEWLINE_xXPregnancy or lactating females; women of childbearing potential must have a negative serum pregnancy test within 7 days prior to registrationXx_NEWLINE_xXPatients with a negative pregnancy test (urine or serum) must be documented within 28 days of starting treatment for women of childbearing potential (WOCBP)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, during the study and for 7 days following the last dose of study treatment.Xx_NEWLINE_xXFemale participants must have a negative pregnancy test at screening if of childbearing potential or be of non-childbearing potentialXx_NEWLINE_xXWomen of childbearing age with a negative pregnancy serum test documented prior to enrollmentXx_NEWLINE_xXA urine pregnancy test (within 7 days of enrollment date) is required for women with childbearing potentialXx_NEWLINE_xXWomen must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXNegative pregnancy test for females of childbearing potentialXx_NEWLINE_xXSubject is of childbearing potential and does not have a negative pregnancy test.Xx_NEWLINE_xXFor females of childbearing potential, must have a negative pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 14 days prior to registration for protocol therapy.Xx_NEWLINE_xXSerum pregnancy test for female patients of childbearing potential, =< 72 hours prior to study entry; women of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy text result has been obtainedXx_NEWLINE_xXWomen of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within 7 days prior to the first dose of study treatment.Xx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration for women of childbearing potential onlyXx_NEWLINE_xXWithin 14 days of enrollment: If female of childbearing potential, urine pregnancy test is negativeXx_NEWLINE_xXNegative pregnancy test for women of childbearing potential (< 51 years of age) as per institutional policyXx_NEWLINE_xXPostmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of IPsXx_NEWLINE_xXA woman of childbearing potential who agrees to use a highly effective contraception (i.e., methods with a failure rate of less than 1 % per year) as detailed in in Appendix VII of this protocol 2 weeks before start of first dose of study treatment, during the treatment period and for at least 4 weeks after the last dose of study treatment. Women of childbearing potential must have a negative pregnancy test (?-HCG test in serum) prior to enrollment.Xx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy test within 14 days of treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 28 days of study entryXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential onlyXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 2 weeks prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXPatient of childbearing potential must have a negative serum pregnancy test prior to study entry and must be practicing and effective form of birth controlXx_NEWLINE_xXFemale subject of childbearing potential should have a negative pregnancy test or documentation of absence of pregnancy by a gynecologist within 2 weeks of initiating radiation therapyXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant and/or breastfeeding; patients of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of the administration of the first study treatment; women must not be lactating; both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the studyXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 30 days prior to randomization. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.Xx_NEWLINE_xXWomen must not be pregnant or breast-feeding\r\n* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program\r\n* All females of childbearing potential must have a blood test within 2 weeks prior to registration to rule out pregnancy \r\n* Pregnancy testing is not required for post-menopausal or surgically sterilized womenXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception. If applicable, patients must discontinue breastfeeding prior to study entry.Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to receiving study agentsXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy within 2 weeks prior to starting radiation therapy or undergoing ablationXx_NEWLINE_xXNegative urine or serum pregnancy test done =< 7 days prior to registration/randomization, for women of childbearing potential only\r\n* NOTE: in the rare case that a woman enrolling on study is of childbearing potential, a pregnancy test is required prior to enrollment on studyXx_NEWLINE_xXNegative serum or urine pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for 12 months or no previous surgical sterilization, within one week prior to initiation of treatment; WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within the 14-day period prior to randomization. (Where demanded by local regulations, this test may be required within 72 hours of randomization.)Xx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only; note: post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigatorXx_NEWLINE_xXWomen who are pregnant or breast-feeding; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXPregnant and/or breastfeeding; patients that are of childbearing age must have a negative pregnancy test at screening and agree on using contraception during the duration of the studyXx_NEWLINE_xXPregnant and/or breastfeeding: patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy testXx_NEWLINE_xXPregnant or lactating, or intending to become pregnant during the study: Women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drugXx_NEWLINE_xXFor women of childbearing potential, a negative serum pregnancy test =< 7 days prior to registrationXx_NEWLINE_xXNegative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)Xx_NEWLINE_xXFemales of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.Xx_NEWLINE_xXPregnant as determined by a positive serum pregnancy test within 14 days prior to registration on study (for females of childbearing potential)Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing age must have negative pregnancy testXx_NEWLINE_xXFemale participants of childbearing potential must have a negative urine or serum pregnancy test and must be willing to use 2 adequate methods of contraception starting with the screening visit through 120 days after the last dose of pembrolizumabXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use effective contraception, during the study and for 30 days following the last dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXA woman of childbearing potential must have a negative serum pregnancy test at screening within 14 days prior to randomizationXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 14 days of radiation startXx_NEWLINE_xXNegative pregnancy test (women of childbearing potential)Xx_NEWLINE_xXNegative serum or urine pregnancy test within 2 weeks prior to registration for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 7 days of the start of study drug administrationXx_NEWLINE_xXNegative pregnancy test within 7 days prior to starting the study premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 yearXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemales should be using adequate contraceptive measures should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potentialXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraception during the study and for at least 6 months after receiving the final treatment of bevacizumab and/or olaparibXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 2 weeks prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXNegative pregnancy test (women of childbearing potential only)Xx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period they are receiving the study drug and for 3 months thereafter; abstinence is an acceptable method of birth control; women of childbearing potential will be given a pregnancy test within 7 days prior to administration of PD-0325901 and must have a negative urine or serum pregnancy testXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test and agree to ongoing pregnancy testing and to practice contraception; (birth control methods should be determined in consultation with the investigator)Xx_NEWLINE_xXFor female participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment.Xx_NEWLINE_xXWomen of childbearing potential must have negative serum pregnancy test performed within 7-days prior to registrationXx_NEWLINE_xXFemales of childbearing potential should have a negative pregnancy testXx_NEWLINE_xXFemales of childbearing potential have a negative serum pregnancy test.Xx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have negative pregnancy test within 7 days prior to day 1 (D1) of treatmentXx_NEWLINE_xXIf female of childbearing potential, negative pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test at ScreeningXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 30 days prior to study registration. Women should be counseled regarding acceptable birth control methods to utilize from the time of screening to start of treatment. If prior to treatment after discussion with the subject it is felt by the treating physician there is a possibility the subject is pregnant a pregnancy test should be repeated. Women of childbearing potential must have a negative pregnancy test within 30 days prior to study registration.Xx_NEWLINE_xXWomen must not be pregnant or lactating; women of reproductive-potential must have negative serum or urine pregnancy test within 7 days prior to study enrollment and agree to use an effective method to avoid pregnancy during and for 30 days following last cessation drug doseXx_NEWLINE_xXIf patient is of childbearing potential, she must have a negative blood or urine pregnancy test within 14 days of surgical treatment on studyXx_NEWLINE_xXNegative serum pregnancy test within 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXFemales who are breastfeeding or pregnant. For females of childbearing potential, a negative screening pregnancy test must be obtained within 72 hours before the first dose of study drugXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential must have negative serum pregnancy test =< 21 days prior to starting study treatmentXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPatients with reproductive potential (for example, females menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures for the duration of study drug therapy and for at least 30 days after completion of study drug therapy; female patients of childbearing potential must provide a negative pregnancy test (serum or urine) =< 14 days prior to treatment initiationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test =< 7 days prior to registrationXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 14 days of registrationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXA positive serum pregnancy test within 14 days prior to treatment in women of childbearing potentialXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum pregnancy test within 14 days before the start of the treatment; women of childbearing potential may have a urine pregnancy test, instead of a serum pregnancy test; if either the serum or urine pregnancy test is equivocally negative the patient will be eligible for the protocol; women of childbearing potential must agree to use an adequate method of contraception during the study until 30 days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatmentXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy test; the anti-proliferative activity of this experimental drug may be harmful to the developing fetusXx_NEWLINE_xXPregnant or breastfeeding patients; women of childbearing potential must have a documented negative pregnancy test a maximum of 7 days before start of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test at screeningXx_NEWLINE_xXPremenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopauseXx_NEWLINE_xXPregnant and/or breastfeeding; premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXNegative pregnancy test performed =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollmentXx_NEWLINE_xXFor females with reproductive potential: a negative serum pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 7 days prior to study treatmentXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to enrollment in female subjects with reproductive potentialXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXNegative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus)Xx_NEWLINE_xXNegative serum or urine pregnancy test; the pregnancy test result must be obtained prior to the first administration of AUY922 (=< 14 days prior to dosing) in all pre-menopausal women and women < 2 years after the onset of menopauseXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy test.Xx_NEWLINE_xXThe patient is a woman who is pregnant or lactating; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; all patients (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 30 days after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test during Screening Period and within 48 hours of the first dose of ARQ 087.Xx_NEWLINE_xXPregnant females are excluded; women of childbearing age/menstruating must confirm that they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapyXx_NEWLINE_xXWomen of childbearing potential only: negative pregnancy test done =< 7 days prior to registrationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum/urine pregnancy testXx_NEWLINE_xXFemale patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test; women of child-bearing potential must have a negative pregnancy test prior to the first dose of bevacizumab; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following the discontinuation of bevacizumab; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medicationXx_NEWLINE_xXPatient must not be pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entryXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; women of child bearing potential must undergo pregnancy testing prior to each dose if the previous pregnancy test was greater than 14 days prior and a pregnancy test at 6 months after the last doseXx_NEWLINE_xXNegative serum pregnancy test within 7 days of commencement of treatment in premenopausal womenXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 7 days of starting treatmentXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXPregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potentialXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test in females of reproductive ageXx_NEWLINE_xXPregnancy or breast feeding - women of childbearing potential must have a negative pregnancy test within 28 days of study enrollmentXx_NEWLINE_xXBoth men and women may be enrolled; premenopausal females must have a negative pregnancy test prior to treatment and lactating females will have to discontinue breast feeding to be eligibleXx_NEWLINE_xXWomen of childbearing potential must have negative blood or urine pregnancy test at screeningXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential with negative serum pregnancy test prior to randomisationXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXIf female of childbearing potential, pregnancy test is negativeXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential onlyXx_NEWLINE_xXFemale subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXPatients of childbearing age must have a negative pregnancy testXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXWomen not of childbearing potential must be postmenopausal, permanently sterilized, or otherwise incapable of pregnancyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollmentXx_NEWLINE_xXWomen of childbearing potential must have a negative beta-HCG pregnancy test documented within 2 weeks prior to registration.Xx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative, qualitative serum pregnancy test =< 2 weeks prior to study entryXx_NEWLINE_xXFemale patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinibXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potentialXx_NEWLINE_xXFemale patients of childbearing potential (not postmenopausal for at least 12 months and not surgically sterile) must have a negative serum or urine pregnancy test within 14 days of study registration; pregnancy test must be repeated if performed > 14 days before starting study drugXx_NEWLINE_xXFemale subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to the start of pazopanib treatment and both men and women must be willing to use adequate contraceptionXx_NEWLINE_xXPregnant females are excluded; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of radiation therapyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days before the first dose of study treatment and agree to use effective contraception during the study; NOTE: Oral contraceptives are not reliable due to potential drug-drug interaction with dabrafenib.Xx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potential; this is a female who has not been postmenopausal for at least 12 consecutive months or who has not undergone previous surgical sterilizationXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to treatmentXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to everolimus initiationXx_NEWLINE_xXPregnant or breastfeeding patients; women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of FOLFIRI treatment, and a negative result must be documented before start of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of the administration of the first study treatment; women must not be lactating; both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the studyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemales with childbearing potential must have had a negative serum pregnancy test less than or equal to 7 days prior to the first dose of study drugXx_NEWLINE_xXWomen must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test at the time of transition to this study and before the first dose of study treatmentXx_NEWLINE_xXA FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug; the first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing the study drug; the subject may not receive study drug until the investigator has verified that the results of these pregnancy tests are negativeXx_NEWLINE_xXNegative pregnancy test (if woman of childbearing potential)Xx_NEWLINE_xXNegative urine or serum pregnancy test in women with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization), within one week prior to initiation of treatmentXx_NEWLINE_xXFor females of childbearing potential, a serum pregnancy test within 2 weeks prior to registration; note: if pelvic irradiation is to be given, the serum pregnancy test must be repeated within 48 hours prior to registrationXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 14 days of the start of study drug. Both men and women enrolled in this study must agree to use adequate birth control measures while on studyXx_NEWLINE_xXWomen of childbearing age must have a negative serum or urine pregnancy test prior to the initiation of study drug.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test upon study entryXx_NEWLINE_xXFemale patient who is of childbearing potential must have a negative serum pregnancy test result within 3 weeks prior to starting study drugs.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy within 28 days prior to receiving the first dose of study medicationXx_NEWLINE_xXWomen of childbearing potential need to have a negative serum pregnancy test at the time of therapyXx_NEWLINE_xXSerum or urine pregnancy test (for women of childbearing potential) negative =< 7 days of starting treatmentXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test (by serum beta-HCG) within 7 days prior to the start of treatment.Xx_NEWLINE_xXPostmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1;Xx_NEWLINE_xXof childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at screening, and agree to one of the following:Xx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potential;Xx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 2 weeks prior to the start of treatmentXx_NEWLINE_xXWomen of childbearing age must have a negative serum pregnancy test, and adequate contraception method(s) must be documentedXx_NEWLINE_xXPatients with reproductive potential (eg, females menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures for the duration of study drug therapy and for at least 30 days after completion of study drug therapy; female patients of childbearing potential must provide a negative pregnancy test (serum or urine) =< 14 days prior to treatment initiationXx_NEWLINE_xXPregnant females are excluded; women of childbearing age/menstruating must confirm that they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test and agree to use a medically accepted form of contraception from the time of initial screening through completion of the studyXx_NEWLINE_xXWomen must not be pregnant or breast-feeding\r\n* All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollmentXx_NEWLINE_xXNegative serum pregnancy test within <30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopauseXx_NEWLINE_xXWomen of childbearing potential have a negative pregnancy testXx_NEWLINE_xXWomen of childbearing potential (not surgically sterilized or at least 2 years postmenopausal) must have a negative serum or urine pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXPregnancy or nursing mothers; women of childbearing potential must have a negative pregnancy test and must agree to use adequate contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration for women of childbearing potential onlyXx_NEWLINE_xXSerum/urine pregnancy test (for females of childbearing potential) negative at screening and before the patient will receive the study treatment.Xx_NEWLINE_xXA woman of childbearing potential must have a negative serum or urine pregnancy test within 14 days before commencing treatment. Females of reproductive potential must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneouslyXx_NEWLINE_xXNegative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization), no more than 7 days before the first dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.Xx_NEWLINE_xXFor women of childbearing potential, negative serum pregnancy test;Xx_NEWLINE_xXNegative urine or serum pregnancy test =< 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test in females of childbearing potentialXx_NEWLINE_xXSubjects with reproductive potential must have a negative pregnancy test within 14 days before randomizationXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential must have a negative serum pregnancy 10-14 days prior to registration, and again within 24 hours prior to the first dose of lenalidomideXx_NEWLINE_xXFemale subject of childbearing potential must have a negative serum pregnancy 10-14 days prior to registration, and again within 24 hours prior to the first dose of lenalidomide; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXIf female of childbearing potential, participant presents with a negative blood pregnancy testXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have negative pregnancy test within 7 days prior to day 1 (D1) of treatmentXx_NEWLINE_xXPregnant or breastfeeding; a negative blood-pregnancy test is required for women of childbearing potential (WOCBP) within 14 days prior to her computed tomography (CT) stimulation for treatment planningXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancyXx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative serum pregnancy test pregnancy test done =< 7 days prior to pre-registration is requiredXx_NEWLINE_xXNegative serum test for pregnancy in premenopausal womenXx_NEWLINE_xXSubjects of reproductive potential must agree to the use of acceptable contraceptive methods for the duration of the time on study and a further 6 months after completion of treatment; women of childbearing potential must have a negative blood or urine pregnancy test within 72 hours of start of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test performed ? 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and during the 3 months following completion of study treatment.Xx_NEWLINE_xXNegative urine pregnancy test within 7 days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without urine pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 yearXx_NEWLINE_xXNon-pregnant and non-nursing women\r\n* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment\r\n* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participationXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an intentional pregnancyXx_NEWLINE_xXFemale patients cannot be of childbearing age, or if they are, must have a negative pregnancy test prior to enrollment and be willing to use contraceptives during treatment and continue for 6 additional monthsXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXFemale patient of childbearing potential has a negative pregnancy test within 14 days prior to the start of study drug.Xx_NEWLINE_xXNegative serum or urine pregnancy test within 7 days prior to study treatment in premenopausal women and women </= 2 years after menopause (menopause is defined as amenorrhea for >/= 2 years)Xx_NEWLINE_xXNegative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potentialXx_NEWLINE_xXFor women of childbearing potential, a negative serum pregnancy test completed prior to any radiation therapyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXPositive pregnancy test in women of childbearing potentialXx_NEWLINE_xXWomen of reproductive potential must have negative urine pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test for women of childbearing potential within 7 days of starting study treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 3 months following the last dose of study treatmentXx_NEWLINE_xXFemale patients who are not of childbearing potential, and female patients of childbearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test within 72 hours prior to start of treatment.Xx_NEWLINE_xXPregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women are excluded; breastfeeding must be discontinuedXx_NEWLINE_xXFemale subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of study treatmentXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test at screening; patients taking oral contraceptives should use an additional method of contraceptionXx_NEWLINE_xXNegative pregnancy test done =< 14 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or breast-feeding women; women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of start of treatmentXx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 48 hours prior to the start of the study drugXx_NEWLINE_xXNegative serum pregnancy test within 14 days prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test =< 7 days prior to pre-registration for women of childbearing potentialXx_NEWLINE_xXFor women of childbearing potential (WOCBP), a negative serum pregnancy test result at Screening.Xx_NEWLINE_xXNegative urine pregnancy test for women of childbearing potentialXx_NEWLINE_xXNegative pregnancy test for Females of childbearing potential.Xx_NEWLINE_xXAdequate bone marrow function Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 14 days prior to study initiation.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXPregnant or lactating women are not eligible; women of childbearing potential must have a negative serum or urine pregnancy test completed within 7 days of study treatment; women or men of childbearing potential not using a reliable and appropriate contraceptive method are not eligible; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.Xx_NEWLINE_xXPregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test within 2 weeks prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or lactating; the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk; all females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy; women of childbearing age must use appropriate contraceptive methodXx_NEWLINE_xXFor women of childbearing potential, have a negative pregnancy test (serum or urine) on Day 1 prior to initiating study treatment.Xx_NEWLINE_xXSerum or urine pregnancy test negative within 2 weeks for women of childbearing potentialXx_NEWLINE_xXWomen who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control; women of childbearing potential must have a negative serum pregnancy test within 24hrs prior to receiving the first dose of study medicationXx_NEWLINE_xXPregnant or breast feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test (urine or serum) performed within 7 days prior to the start of study drug.Xx_NEWLINE_xXNegative serum pregnancy test for female subjects with reproductive potential =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen able to conceive and unwilling to practice an effective method of birth control from screening until 90 days after discontinuing study treatment (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of PQR309).Xx_NEWLINE_xXWomen of childbearing potentialXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test result within 7 days prior to the first dose of study drug.Xx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXNegative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).Xx_NEWLINE_xXPregnant or lactating women; female subjects of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of treatment; (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXPatients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screeningXx_NEWLINE_xXWomen must have a negative serum pregnancy testXx_NEWLINE_xXNegative serum pregnancy test for pre-menopausal women and women within 12 months from the onset of menopauseXx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXNegative pregnancy test (urine dipstick or serum) for women of childbearing potential within 2 weeks prior to registrationXx_NEWLINE_xXNegative serum or urine pregnancy test must be obtained within 7 days before the first dose of study drug in women of childbearing potential. Negative results must be available before study drug administrationXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a serum pregnancy test performed within 28 days prior to the first day of study drug dosing.Xx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing age must have a negative urine pregnancy testXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative pregnancy test performed prior to the start of study drugXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to starting study treatment in premenopausal women and women less than (< 2) years after the onset of menopauseXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the start of SL-701 treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception as defined in the protocol.Xx_NEWLINE_xXFemale subjects of childbearing age must have a negative serum pregnancy test at study entryXx_NEWLINE_xXFemale patients of childbearing potential must be non-pregnant, non-lactating, and have a negative pregnancy test result prior to enrollment in the study;Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.Xx_NEWLINE_xXIf the subject is a female of childbearing potential, has she had a negative serum pregnancy test within the past 21 days?Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a blood or urine pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatmentXx_NEWLINE_xXPregnant and/or breastfeeding women; women of childbearing potential must have a negative serum pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative pregnancy test for pre-menopausal womenXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test at the screening visit.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 30 days following the last dose of investigational product.Xx_NEWLINE_xXWomen of childbearing potential only: negative serum pregnancy test done =< 7 days prior to registrationXx_NEWLINE_xXWomen of childbearing potential (WOCBP) who have a positive serum pregnancy test within 14 days of the first administration of oral dasatinibXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception prior to the study entry, for the duration of study participation and up to 3 months following completion of therapy. Women of childbearing potential must have a negative pregnancy test within 7 days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.Xx_NEWLINE_xXWomen of childbearing potential must have a negative urine pregnancy test performed within 7 days before start of study treatmentXx_NEWLINE_xXNegative results of serum pregnancy test for premenopausal women of reproductive capacity and for women < 12 months after entering menopauseXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and agree to use effective contraception, during the study, and for 30 days after the last dose of study treatmentXx_NEWLINE_xXFor women of childbearing potential, the participant must have a negative pregnancy test at screening and must agree to employ 2 forms of adequate contraceptive measuresXx_NEWLINE_xXNegative serum or urine pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for 12 months or no previous surgical sterilization, within one week prior to initiation of treatment; WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancyXx_NEWLINE_xXWomen of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 10 to 14 days and again within 24 hours of starting study drugXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test at baseline prior to receiving any study drug and must practice effective contraception while on study; (pregnant or lactating patients are excluded)Xx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative (serum) pregnancy test done =< 7 days prior to registration, for women of childbearing potential only; NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as age >= 50 years and no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative blood pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXFemale patient has a negative serum pregnancy test within 72 hours prior to taking study drug if of childbearing potential, and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential.Xx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to administration of everolimusXx_NEWLINE_xXFemale patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXFemale patient of childbearing potential has a negative pregnancy test within 14 days prior to the start of study drugXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test before study entry.Xx_NEWLINE_xXIf female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.Xx_NEWLINE_xXNegative serum or urine pregnancy test for women of childbearing potential onlyXx_NEWLINE_xXNegative serum pregnancy test within 14 days before starting study treatment in women with childbearing potentialXx_NEWLINE_xXFemales (childbearing potential): Have had a negative serum pregnancy test before the first dose of study drug and not be breast-feeding.Xx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatmentXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test; patients of childbearing potential must agree to use an effective birth control methodXx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test to be eligibleXx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXIf the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, then she must practice adequate contraception for 30 days prior to treatment administration, have a negative pregnancy test and continue such precautions for 2 months after completion of the treatment administration series.Xx_NEWLINE_xXIf a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study treatment and for up to 4 weeks following SBRTXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy.Xx_NEWLINE_xXFemale subject of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXPregnant or lactating women are not eligible; women of childbearing potential must have a negative serum pregnancy test completed within 7 days of study entry, and use an appropriate form of birth control throughout the trial periodXx_NEWLINE_xXWomen of childbearing potential must have had a negative pregnancy test (urine or serum) ? 7 days prior to enrollment, and willingness to use an acceptable method of contraception during participation in the study and for 3 months after the last dose.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test prior to azacitidine treatmentXx_NEWLINE_xXIf the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate con-traception for 30 days prior to treatment administration, have a negative pregnancy test and continue such pre-cautions for two months after completion of the treatment administration series.Xx_NEWLINE_xXNot pregnant and not nursing\r\n* For women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is requiredXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration, for persons of childbearing potential onlyXx_NEWLINE_xXWomen who are pregnant or breast-feeding; women of childbearing potential with a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception (including two forms of contraception, one of which must be a barrier method) in the opinion of the investigator; perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potentialXx_NEWLINE_xXFOCBP must have a negative pregnancy test within 14 days prior to registration on studyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to registrationXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entryXx_NEWLINE_xXOr, if of childbearing potential:Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatmentXx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy test at screeningXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXPatients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; pregnant women are excluded from this studyXx_NEWLINE_xXNegative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potential and agrees to use contraception for the duration of the treatment cycle and for a minimum of 30-days following the end of therapy (a minimum estimate 95 days)Xx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy testXx_NEWLINE_xXNegative pregnancy test done =< 14 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drugXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potentialXx_NEWLINE_xXPregnant or lactating; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration only for women determined to be of childbearing potential by their treating physicianXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =< 14 days prior to registration and confirmation they are not nursing is requiredXx_NEWLINE_xXWomen of childbearing age must have a negative serum pregnancy test within 14 days prior to registrationXx_NEWLINE_xXIn addition, women of childbearing potential must consent to use adequate contraception throughout protocol therapy; females of childbearing potential must have a negative urine pregnancy test =< 7 days prior to registrationXx_NEWLINE_xXPremenopausal women (including women who have had a tubal ligation and for women less than 12 months after the onset of menopause) must have a negative serum pregnancy testXx_NEWLINE_xXFemales of childbearing potential have a negative pregnancy test within 72 hours prior to initiating study drug dosingXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test and agree to practice a medically acceptable contraception regimen for the study duration. Women who are postmenopausal for at least 1 year (> 12 months since last menses) or are surgically sterilized do not require this testXx_NEWLINE_xXWomen of childbearing potential must have a negative urine pregnancy test at screening, andXx_NEWLINE_xXFemales of childbearing potential who:Xx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entryXx_NEWLINE_xXNon-pregnant; women of childbearing potential must have a negative pregnancy test to participate in this studyXx_NEWLINE_xXPregnant females (women of childbearing potential must have a negative serum pregnancy test prior to enrollment)Xx_NEWLINE_xXNegative pregnancy test at study registrationXx_NEWLINE_xXPregnant women will also be excluded (Phase I, part B and Phase II); all female participants who are pregnant or become pregnant over the course of the study are not eligible to participate; women of childbearing potential will be asked to complete a blood pregnancy test (using 1 teaspoon of blood drawn from a vein by needle stick) at their first study visit, and the test must be negative before the woman can continue in the study; women of childbearing potential will be asked to agree to use appropriate contraceptive measures for the duration of the study; participants with medically verified menopausal status (e.g., via tests of ovarian functioning documented in the participants’ medical record) will not be asked to complete a blood pregnancy testXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative serum pregnancy test within 2 weeks prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXFemale patients of childbearing age must have a negative pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test result and must agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug\r\n* Childbearing potential is defined as girls who are > Tanner stage 2, except for those who have documented pan pituitary insufficiency or other hormonal state incompatible with pregnancy\r\n* Urine pregnancy tests are acceptableXx_NEWLINE_xXFor females of childbearing potential, a negative serum pregnancy test must be documented prior to enrollmentXx_NEWLINE_xXIf the patient is of childbearing potential, the patient must have a negative blood or urine pregnancy test within 14 days of surgical treatment on studyXx_NEWLINE_xXSerum pregnancy test negative for females of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test (in women of childbearing potential) =< 14 days prior to Step 2; women of childbearing potential and men who are sexually active must practice adequate contraception while on studyXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration (for women of childbearing potential only)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigatorXx_NEWLINE_xXNegative pregnancy test (serum or urine) done =< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)Xx_NEWLINE_xXNot pregnant; for women of childbearing potential only, a negative pregnancy test done =< 28 days prior to registration is requiredXx_NEWLINE_xXWomen of childbearing potential : negative pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.Xx_NEWLINE_xXNegative (serum or urine) pregnancy test, for women of childbearing potential onlyXx_NEWLINE_xXIf a woman of childbearing potential, a negative serum pregnancy test prior to randomization.Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative plasma pregnancy test upon study entryXx_NEWLINE_xXNegative serum pregnancy test within 2 weeks prior to registration for women of childbearing potentialXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXNegative urine or serum pregnancy test performed =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test; sexually active patients must agree to use contraception prior to, during, and 30 days after last doseXx_NEWLINE_xXNegative (serum) pregnancy test done =< 7 days prior to randomization, for women of childbearing potential onlyXx_NEWLINE_xXNegative serum pregnancy test at the time of enrollment for females of childbearing potentialXx_NEWLINE_xXNonpregnant, nonlactating female patients; patients of childbearing potential must implement an effective method of contraception during the study; all women of childbearing potential must have a pre-study negative serum or urine pregnancy test within 7 days prior to study entryXx_NEWLINE_xXNegative serum pregnancy test for females of childbearing potentialXx_NEWLINE_xXNegative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)Xx_NEWLINE_xXPregnancy; female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days; male patients with reproductive potential will be counseled not to procreate during the studyXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test as per Memorial Sloan-Kettering Cancer Center (MSKCC) guidelinesXx_NEWLINE_xXPregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancyXx_NEWLINE_xXNegative pregnancy test done ? 7 days prior to registration, for women of childbearing potentialXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXFemale patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to starting study drugXx_NEWLINE_xXFemale patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy testXx_NEWLINE_xXWomen of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 days prior to the first study interventionXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXNegative pregnancy test at time of signing consent for women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy testXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXNegative pregnancy test for women of childbearing potentialXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception during the studyXx_NEWLINE_xXFemale patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to enrollmentXx_NEWLINE_xXPregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancyXx_NEWLINE_xXNegative pregnancy test =< 7 days prior to randomizationXx_NEWLINE_xXWomen of childbearing age with a negative pregnancy test documented prior to enrollmentXx_NEWLINE_xXA negative serum pregnancy test at baseline, but within 21 days of randomization, for persons of childbearing potential onlyXx_NEWLINE_xXNot pregnant or nursing; note: a negative (serum or urine) pregnancy test must be documented =< 7 days prior to registration/randomization for women of childbearing potentialXx_NEWLINE_xXA female subject is eligible to participate if she is of: Non-childbearing potential or women of childbearing potential must have a negative serum pregnancy test within 72 hours of first dose of study treatment and agree to use effective contraception during the study and for 60 days following the last dose of study treatment.Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum pregnancy testXx_NEWLINE_xXA negative serum pregnancy test within 7 days prior to the first dose of Study treatment in women of childbearing potential (ie, all women except those who are post menopause for ? 1 year or who have a history of hysterectomy or surgical sterilization)Xx_NEWLINE_xXA woman of childbearing potential must have a negative serum or urine pregnancy test at screening within 14 days prior to randomizationXx_NEWLINE_xXhas a negative pregnancy test on the day of vaccination, andXx_NEWLINE_xXhas a negative pregnancy test on the day of vaccination, andXx_NEWLINE_xXPregnancy or lactation at the time of study registration; (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to study registration)Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to enrollment, must be non-lactating and must agree to use adequate contraception prior to enrollment and for the duration of study participationXx_NEWLINE_xXIf of childbearing potential, the patient has a negative pregnancy test within 72 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 yearXx_NEWLINE_xXIndividuals not pregnant at enrollment; female subjects of childbearing potential will undergo a pregnancy test prior to imagingXx_NEWLINE_xXIndividuals not pregnant at enrollment; female subjects of childbearing potential will undergo a pregnancy test prior to imagingXx_NEWLINE_xXWomen of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative pregnancy test or who are lactatingXx_NEWLINE_xXPatients must not be pregnant or breast feeding; women of childbearing potential are required to obtain a negative pregnancy test within 14 days of starting treatment; effective contraception (men and women) must be used in subjects of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy testXx_NEWLINE_xXWomen of childbearing potential (WCBP): negative serum pregnancy test, obtained within 14 days prior to PET scanXx_NEWLINE_xXWomen who are pre-menopausal must have a negative serum pregnancy testXx_NEWLINE_xXNegative pregnancy test within 7 days prior to starting the study in premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 yearXx_NEWLINE_xXFemales who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential at screeningXx_NEWLINE_xXPatients of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to PET/CT imaging per institution’s standard of care.Xx_NEWLINE_xXWomen of reproductive potential must have a urine pregnancy test day of injectionXx_NEWLINE_xXWomen of childbearing potential who refuse a pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test (urine or blood) pre-operatively as per the standard hospital policy; a woman of childbearing potential is defined as one who is biologically capable of becoming pregnantXx_NEWLINE_xXBreastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.Xx_NEWLINE_xXPregnant or breast feeding women are excluded from this study; women of childbearing potential must have a negative pregnancy test within 3 days prior to receiving indocyanine greenXx_NEWLINE_xXSubject is male; or is a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), >= 60 years old, or of childbearing potential for whom a pregnancy test (with the results known prior to investigational product administration) is negative; a negative pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is not capable of becoming pregnant; female must also be non-lactatingXx_NEWLINE_xXNegative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained < 2 weeks prior to study enrollmentXx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test no more than 3 days prior to FDOPA injectionXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potentialXx_NEWLINE_xXWomen who are pre-menopausal must have a negative serum pregnancy testXx_NEWLINE_xXNegative pregnancy test, to be performed on female patients of childbearing potential within 1 week before administration of radioactive materialXx_NEWLINE_xXWomen of childbearing age must have a negative blood pregnancy testXx_NEWLINE_xXNegative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC standards & guidelines), from assays obtained < 2 weeks prior to study enrollment; patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the studyXx_NEWLINE_xXWomen who are pre-menopausal must have a negative serum pregnancy testXx_NEWLINE_xXWomen must not be pregnant or breast-feeding as the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to first PET/MRIXx_NEWLINE_xXSubject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative; a negative serum pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnantXx_NEWLINE_xXPregnancy or breastfeeding; women of childbearing potential must have a negative pregnancy test prior to undergoing MRI/PET imaging; post-menopausal status may be established by patient reported history of absence of menses over the last 12 monthsXx_NEWLINE_xXWomen of childbearing potential who refuse a pregnancy test (performed during screening)Xx_NEWLINE_xXPregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done)Xx_NEWLINE_xXNegative serum pregnancy test (female of childbearing potential only)Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine) within the 7 days prior to study drug administration, and within the 3 days before the first study drug administration, or a negative pregnancy test within the 24 hours before the first study drug administration.Xx_NEWLINE_xXWomen must have a negative serum pregnancy test within 7 days prior to the first dose of study drug or be surgically or biologically sterile or postmenopausalXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment.Xx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for women of childbearing potential onlyXx_NEWLINE_xXPregnant or breastfeeding (negative serum or urine pregnancy test required for women of childbearing potential), or unable to maintain use of contraception while on study and for 60 days after the last dose of avelumabXx_NEWLINE_xXOr, if of childbearing potential,Xx_NEWLINE_xXSubject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative; a negative serum pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnantXx_NEWLINE_xXPositive serum or urine pregnancy test within 24 hours of imaging prior to injection of radiotracer (for women of childbearing potential per Radiology Department clinical guidelines)Xx_NEWLINE_xXIf of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 yearXx_NEWLINE_xXif female of childbearing potential must have a negative pregnancy test within 24 hours of enrollmentXx_NEWLINE_xXFor females: negative serum pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomyXx_NEWLINE_xXAll females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXIf female of childbearing potential, pregnancy test is negative; (in these instances, the patient will need to provide documentation of negative pregnancy test results)Xx_NEWLINE_xXWomen of childbearing potential will undergo a pregnancy testXx_NEWLINE_xXWomen of childbearing age must have a negative pregnancy test at screening/baselineXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to infusionXx_NEWLINE_xXAll females of childbearing age must have a negative pregnancy test before beginning the studyXx_NEWLINE_xXWomen of childbearing potential will be required to have a urine pregnancy testXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test prior to the administration of protocol specified interventionsXx_NEWLINE_xXNegative urine pregnancy test for women of childbearing potential within 7 days of baseline [D10]phe dosingXx_NEWLINE_xXNegative serum pregnancy test at screening for women of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women <= 2 years after start of menopauseXx_NEWLINE_xXPregnant or lactating women; all pre-menopausal women being screened must have a negative serum pregnancy test within 14 days prior to commencement of dosing; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 yearXx_NEWLINE_xXWomen of childbearing age will have to undergo a pregnancy test that will be provided free of chargeXx_NEWLINE_xXCriteria 9, Female subjects of childbearing potential should have a negative serum pregnancy test within 1 week prior to enrollmentXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the restart of study drugXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.Xx_NEWLINE_xXWomen of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scanXx_NEWLINE_xXFor women of childbearing potential, negative serum pregnancy test within 7 days of enrollmentXx_NEWLINE_xXNegative serum or urine pregnancy test must be obtained within 7 days prior to the first dose of study drug in women of childbearing potential. Negative results must be available prior to study drug administration. Pregnancy tests will be repeated regularly during treatmentXx_NEWLINE_xXPregnant women. Women of reproductive potential must have a negative serum or urine pregnancy test performed within 7 dayXx_NEWLINE_xX